Sanofi Invests To Build Internal Capabilities in mRNA

Sanofi SA SNY is working towards its R&D approach around mRNA to accelerate the development and delivery of next-generation vaccines.
The company will invest approximately €400 million per year to build out its “end-to-end” internal capabilities in mRNA, the cell therapy technology.
Sanofi said the plan is to piece together a team of around 400, spread across R&D, digital, chemistry, manufacturing & controls to advance mRNA technology in non-pandemic indications.
The team will be spread across two centers in Cambridge, MA, and Marcy l’Etoile, near Lyon, France.
With this investment, Sanofi hopes to have six clinical candidates in the fold by 2025, which it calls the “expected minimum.”
Though it did not disclose the therapeutic areas it hoped to address, the company said its focus would be on “diseases of high unmet need.”
Price Action: SNY shares are down 1% at $52.69 during the premarket session on the last check Tuesday.